7,093 reports of this reaction
3.4% of all METOCLOPRAMIDE HYDROCHLORIDE reports
#4 most reported adverse reaction
DYSTONIA is the #4 most commonly reported adverse reaction for METOCLOPRAMIDE HYDROCHLORIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 7,093 FDA adverse event reports linking METOCLOPRAMIDE HYDROCHLORIDE to DYSTONIA. This represents approximately 3.4% of all 206,778 adverse event reports for this drug.
Patients taking METOCLOPRAMIDE HYDROCHLORIDE who experience dystonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSTONIA is moderately reported among METOCLOPRAMIDE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to dystonia, the following adverse reactions have been reported for METOCLOPRAMIDE HYDROCHLORIDE:
The following drugs have also been linked to dystonia in FDA adverse event reports:
DYSTONIA has been reported as an adverse event in 7,093 FDA reports for METOCLOPRAMIDE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSTONIA accounts for approximately 3.4% of all adverse event reports for METOCLOPRAMIDE HYDROCHLORIDE, making it a notable side effect.
If you experience dystonia while taking METOCLOPRAMIDE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.